In the most recent trading session, DaVita HealthCare (DVA) closed at $151.37, indicating a +0.39% shift from the previous trading day.
DVA's stable core business and global expansion are offset by rising labor costs and declining commercial mix, creating a mixed outlook for investors.
DaVita HealthCare (DVA) reachead $150.78 at the closing of the latest trading day, reflecting a +0.25% change compared to its last close.
The latest trading day saw DaVita HealthCare (DVA) settling at $149.83, representing a +0.31% change from its previous close.
DaVita HealthCare (DVA) closed the most recent trading day at $141.12, moving -1.06% from the previous trading session.
Shares of Davita Inc. (NYSE: DVA) plunged 11% on February 14, as the dialysis provider issued a weaker-than-expected 2025 earnings outlook, citing rising patient care costs, supply constraints, and ongoing dialysis center closures.
Shares of DaVita Inc (DVA -11.09%) are trading lower on Friday. The company's stock lost 11.1% as of market close but lost as much as 15.2% earlier in the day.
DaVita shares were tumbling 13.5% Friday to lead S&P 500 decliners, after Warren Buffett's Berkshire Hathaway pared its stake in the provider of kidney dialysis.
Warren Buffett, the ‘Oracle of Omaha', managed to attain a roughly $142 billion net worth by consistently outperforming the markets. The Berkshire Hathaway (NYSE: BRK.B) chief executive officer (CEO) and chairman did so by utilizing a careful, level-headed approach to investing.
DaVita shares tumbled after issuing a weak outlook amid rising care costs, while big investor Berkshire offloaded some shares in a pre-planned agreement.
DaVita Inc. (NYSE:DVA ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Nic Eliason - Group VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO Conference Call Participants Joanna Gajuk - Bank of America AJ Rice - UBS Pito Chickering - Deutsche Bank Justin Lake - Wolfe Research Andrew Mok - Barclays Ryan Langston - TD Cowen Operator Good evening. My name is Michelle, and I will be your conference facilitator today.
Berkshire Hathaway said on Thursday night it sold 203,091 shares of DaVita , reducing its stake in the kidney dialysis services provider to about 35.89 million shares, a 45% stake worth nearly $6.4 billion.